PL425832A1 - Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera - Google Patents

Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera

Info

Publication number
PL425832A1
PL425832A1 PL425832A PL42583218A PL425832A1 PL 425832 A1 PL425832 A1 PL 425832A1 PL 425832 A PL425832 A PL 425832A PL 42583218 A PL42583218 A PL 42583218A PL 425832 A1 PL425832 A1 PL 425832A1
Authority
PL
Poland
Prior art keywords
alzheimer
disease
treatment
genistein
composition
Prior art date
Application number
PL425832A
Other languages
English (en)
Other versions
PL237739B1 (pl
Inventor
Grzegorz WĘGRZYN
Karolina Pierzynowska
Magdalena Podlacha
Dorota Myślińska
Irena Majkutewicz
Lidia Gaffke
Original Assignee
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Gdański filed Critical Uniwersytet Gdański
Priority to PL425832A priority Critical patent/PL237739B1/pl
Priority to EP19177784.6A priority patent/EP3583942B1/en
Publication of PL425832A1 publication Critical patent/PL425832A1/pl
Publication of PL237739B1 publication Critical patent/PL237739B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia są genisteina do zastosowania w leczeniu choroby Alzheimera, które stosuje się w dawce 150/mg/kg/dzień. Przedmiotem zgłoszenia jest także zastosowanie genisteiny do wytwarzania preparatu farmaceutycznego do leczenia choroby Alzheimera oraz kompozycja farmaceutyczna zawierająca genisteinę w dawce 150/mg/kg/dzień i co najmniej jeden dopuszczalny farmaceutycznie nośnik do zastosowania w leczeniu choroby Alzheimera.
PL425832A 2018-06-06 2018-06-06 Genisteina do zastosowania do leczenia choroby Alzheimera PL237739B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL425832A PL237739B1 (pl) 2018-06-06 2018-06-06 Genisteina do zastosowania do leczenia choroby Alzheimera
EP19177784.6A EP3583942B1 (en) 2018-06-06 2019-05-31 Genistein for use in a method of treatment of alzheimer's disease as stimulator of the autophagy process in a process of lysosomal system activation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL425832A PL237739B1 (pl) 2018-06-06 2018-06-06 Genisteina do zastosowania do leczenia choroby Alzheimera

Publications (2)

Publication Number Publication Date
PL425832A1 true PL425832A1 (pl) 2019-12-16
PL237739B1 PL237739B1 (pl) 2021-05-17

Family

ID=67253645

Family Applications (1)

Application Number Title Priority Date Filing Date
PL425832A PL237739B1 (pl) 2018-06-06 2018-06-06 Genisteina do zastosowania do leczenia choroby Alzheimera

Country Status (2)

Country Link
EP (1) EP3583942B1 (pl)
PL (1) PL237739B1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL440896A1 (pl) 2022-04-11 2023-10-16 Uniwersytet Gdański Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110289A (en) 1993-08-06 1998-01-04 Policlinico San Matteo Istitut Pharmaceutical preparations containing 4-iodo-4-deoxydoxorubicin for the treatment of amyloidosis
ES2177849T3 (es) 1996-08-27 2002-12-16 Nattermann A & Cie Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
ES2246178B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
KR101441725B1 (ko) 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
US9744204B1 (en) * 2015-03-17 2017-08-29 Bryant Richard Villeponteau Multipath nutritional supplement for memory, cognition, and coordination
CN110177572A (zh) 2016-09-12 2019-08-27 史蒂文·霍夫曼 用于治疗痴呆的组合物

Also Published As

Publication number Publication date
PL237739B1 (pl) 2021-05-17
EP3583942B1 (en) 2024-01-10
EP3583942A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12019500025A1 (en) Cancer treatment combinations
NZ763123A (en) Pde9 inhibitor and use thereof
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
CO2021006482A2 (es) Ureas cíclicas
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
PH12021553056A1 (en) Modified release formulations and uses thereof
ZA202000028B (en) Use of vibegron to treat overactive bladder
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
UY28457A1 (es) Nueva composición
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
ZA202200331B (en) Naltrexone formulation